-
-
-
-
-
-
-
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
-
-
-
-
-
-
-
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $172 at Truist Securities
-
-
-
-
-
-
-
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX) Tops Q1 EPS by 13c; reaffirms guidance
-
1,231,050 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


